Clinical trials: Cancer, Ovarian
Polycystic Ovary Syndrome
Combination of D-chiro-inositol With Ketogenic Diet
The study aims to evaluate whether the combination of a product based on D-chiro-inositol and the ketogenic diet can improve the metabolic/endocrine picture of overweight/obese women with PCOS, with insulin resistance, in a…
- Trial name
- NCT05348967
- Testing
- TECADRIOL
- Where
- Italy
- Sponsor
- Lo.Li.Pharma s.r.l
Fallopian Tube Cancer, Ovarian Cancer
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT01493505
- Testing
- AMG 386, Paclitaxel, Carboplatin
- Where
- 310 sites in United States, Austria and 12 more
- Volunteers
- 1,015 people
- Sponsor
- Amgen
Polycystic Ovary Syndrome (PCOS)
App Impact on Quality of Life and Symptoms in PCOS
This study investigates the influence of a PCOS app on the quality of life and symptoms of individuals with polycystic ovary syndrome (PCOS).
- Trial name
- NCT06912594
- Testing
- PCOS-App
- Where
- Germany
- Volunteers
- 220 people
- Sponsor
- Endo Health GmbH
Ovarian Cancer, Fallopian Cancer
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.
- Conditions
- Ovarian Cancer, Fallopian Cancer, Peritoneal Cancer
- Trial name
- NCT01104675
- Testing
- ENMD-2076
- Where
- 6 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- CASI pharmaceuticals, Inc.
Epithelial Ovarian Cancer
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
The purpose of this trial is to assess the safety profile of Cvac for epithelial ovarian cancer patients who were enrolled in the Cvac clinical trial CAN-003 and are no longer eligible for study participation due to disease…
- Trial name
- CAN-003X (NCT01617629)
- Testing
- MUC1 Dendritic Cell Vaccine (Cvac)
- Where
- 6 sites in United States, Australia
- Volunteers
- 9 people
- Sponsor
- Prima BioMed Ltd
Ovarian Neoplasms, Breast Neoplasms
A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)
The objective of this trial is to study the management of PPE in participants with metastatic ovarian or breast cancer treated with Caelyx, and determine the frequency of use of pharmacological treatment (preventive or…
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Paresthesia
- Trial name
- NCT00746694
- Volunteers
- 154 people
- Sponsor
- Merck Sharp & Dohme LLC
Epithelial Ovarian Cancer
Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer
The purpose of this study is to establish the safest dose of MORAb-003 in subjects with advanced ovarian cancer. MORAb-003 is an antibody directed to an antigen on the surface of ovarian cancer cells.
- Trial name
- NCT00428766
- Testing
- MORAb-003
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Morphotek
Ovarian Neoplasms
TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian
Evaluate response rate of Docetaxel in combination with Carboplatin or Cisplatin as first line chemotherapy in epithelial ovarian cancer.
- Trial name
- NCT00539669
- Testing
- Docetaxel
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Sanofi
Cancer, Ovarian, Chemotherapy Effect
Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies
This study evaluates how lifestyle modifications that may be made to manage chemotherapy side effects in patients with gynecologic malignancies.
- Conditions
- Cancer, Ovarian, Chemotherapy Effect, Calorie Deficiency, Fasting, Intermittent
- Trial name
- NCT06376604
- Testing
- Fasting Mimicking Diet, Chemotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- L-Nutra Inc
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks.
- Trial name
- NCT06517433
- Testing
- upifitamab rilsodotin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Mersana Therapeutics
Fallopian Tube Cancer, Ovarian Cancer
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01204749
- Testing
- AMG 386, Paclitaxel
- Where
- 225 sites in United States, Australia and 30 more
- Volunteers
- 919 people
- Sponsor
- Amgen
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Uterine Fibroids (UF), Menstrual Disorders
Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)
The purpose of this research is to evaluate the safety and performance of the investigational Medtronic Hugo™ Robotic Assisted Surgery (RAS) system when used during hysterectomy procedures, including patients being treated for…
- Conditions
- Uterine Fibroids (UF), Menstrual Disorders, Adenomyosis of Uterus, Endometriosis
- Trial name
- Embrace Gyn (NCT07120945)
- Testing
- Robotic Assisted-Surgery (RAS) Hysterectomy
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Medtronic - MITG
Ovarian Cancer
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab…
- Trial name
- FLORENZA (NCT07059845)
- Testing
- Mirvetuximab Soravtansine, Bevacizumab, Carboplatin
- Where
- 86 sites in United States, Australia and 6 more
- Volunteers
- 400 people
- Sponsor
- AbbVie
Cancer
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
- Trial name
- NCT04106492
- Testing
- SQ3370
- Where
- 10 sites in United States, Australia
- Volunteers
- 53 people
- Sponsor
- Shasqi, Inc.
Menstrual Cycle, Ovulation
Apple Women's Health Study
This is an observational longitudinal study to advance the understanding of menstrual cycle and gynecologic health conditions including PCOS, infertility and breast cancer.The study will be hosted within the Research…
- Conditions
- Menstrual Cycle, Ovulation, Menstruation, Polycystic Ovary Syndrome
- Trial name
- NCT04196595
- Where
- United States
- Volunteers
- 500,000 people, healthy volunteers welcome
- Sponsor
- Apple Inc.
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.
- Conditions
- Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
- Trial name
- NCT01209195
- Testing
- MM-121, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Merrimack Pharmaceuticals
Anemia, Breast Cancer
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
This is a multicenter, international, prospective, observational study of patients who are receiving systemic chemotherapy for solid tumour cancers (breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal…
- Conditions
- Anemia, Breast Cancer, Cancer, Colorectal Cancer
- Trial name
- NCT01444456
- Where
- 117 sites in Austria, Belgium and 7 more
- Volunteers
- 1,262 people
- Sponsor
- Amgen
Infertility, Ovulation Induction
To Evaluate the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Pen Compared With Follitropin Beta Liquid Pen
This was a prospective, randomised, open comparative monocentric phase IIIb study to evaluate the convenience, safety and efficacy of follitropin alfa (Gonal-f) liquid pen compared with follitropin beta (Puregon) liquid pen.
- Trial name
- NCT01081639
- Testing
- Follitropin alfa liquid formulation, Follitropin beta liquid formulation
- Volunteers
- 34 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Salvage Ovarian FANG™ Vaccine + Bevacizumab
This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with bevacizumab. All patients will have had Vigil™ prepared and stored from initial primary surgical debulking.
- Trial name
- NCT01551745
- Testing
- Vigil™ Vaccine, Bevacizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Gradalis, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.